Paving The Path In Haematological Cancers

Haematological cancers have always stood apart within oncology in research, disease characteristics and treatment. Whilst the main areas of haem (lymphoma, leukaemia and myeloma) may represent only 7.1% of new cancer cases, this rises to 43% in paediatric cancers. Furthermore, haem represents a high burden of illness and unmet need globally, and as such it is a major focus of innovation, with many breakthrough technologies having emerged here.

This whitepaper will outline the key developments in the haematological cancers space, as they have often pioneered new technologies and procedures, such as stem cell transplants and cell therapies, and the evolving treatment landscape of key indications. This paper will also cover the unique challenges and the critical factors for success regarding the development and commercialisation of assets for haematological cancers.